Top

Discover Oncology

Published in:

Open Access 01-12-2023 | Glioma | Research

Radiotherapy combined with anti-CEACAM1 immunotherapy to induce survival advantage in glioma

Authors: Jinhu Li, Yi Chen, Yimin Fan, Hongqin Wang, Wei Mu, Xiaodong Liu

Published in: Discover Oncology | Issue 1/2023

Abstract

Background

We aimed to observe the effect of radiotherapy on the expression of immune checkpoint molecule CEACAM1 in patients with glioma and the therapeutical effect of radiotherapy combined with blockade of CEACAM1 in mice with intracranial gliomas.

Methods

The expression of CEACAM1 on T-lymphocytes in the peripheral blood of patients with glioma was detected before and after radiotherapy; GL261 murine glioma cells (stably transfected with the luciferase gene) were implanted in the right caudate nucleus of C57BL/6 mice, and tumour growth was observed using the small animal in vivo imaging system. Mice were divided into 4 groups: (1) the isotype control; (2) the radiotherapy; (3) the anti-CEACAM1 treatment; and (4) the combination therapy. The survival of mice after treatment was recorded; the expression of CEACAM1 on murine glioma cells was detected by immunohistochemistry before and after radiotherapy; flow cytometry was adopted to detect CD8⁺ T-cells (Treg) (CD4⁺FoxP3⁺CD25⁺) among mouse brain-infiltrating T-cells; serum levels of IFN-γ and IL-10 were detected by ELISA; proliferation and apoptosis were observed by immunohistochemistry; Retrospective RNA-seq data analysis was conducted in a cohort of 325 patients with glioma in the Chinese Glioma Genome Atlas (CGGA) database and 702 patients in The Cancer Genome Atlas (TCGA) database.

Results

The expression of CEACAM1 on CD4⁺ and CD8⁺ T-cells in the peripheral blood of patients with glioma was significantly higher 1 week after radiotherapy than before radiotherapy and was further increased 1 month after radiotherapy. Combined therapy notably inhibited the growth of intracranial tumours in mice and prolonged their survival time, with some mice being capable of surviving long-term (> 90 d). Immunohistochemistry revealed that the expression of CEACAM1 in murine glioma tissues after radiotherapy was elevated in a time-dependent manner. Flow cytometry analysis showed an increase in mouse brain-infiltrating CD8⁺ T-lymphocytes, a decrease in Treg cells, and an increase in CD8⁺ T/Treg cells after treatment. ELISA demonstrated the elevated levels of IFN and decreased levels of IL-10 in the serum of mice in the combination therapy group.

Conclusions

Radiotherapy combined with CEACAM1 inhibitors resulted in strong and durable anti-tumour immune responses against murine glioma and long-term survival of some mice. Hence, this study is expected to offer new effective immunotherapy strategies against glioma.

Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96. https://doi.org/10.1056/NEJMoa043330.CrossRefPubMed

Li J, Liu M, Sun P, et al. Three-Dimensional conformal radiotherapy combined with gemcitabine and docetaxel in the treatment of advanced bladder cancer and its effects on inflammatory factors and immune function. J Oncol. 2022;2022:9347218.PubMedPubMedCentral

Strepkos D, Markouli M, Klonou A, et al. Insights in the immunobiology of glioblastoma. J Mol Med. 2020;98(1):1–10. https://doi.org/10.1007/s00109-019-01835-4.CrossRefPubMed

Zengfu Zhang Xu, Liu DC, et al. Radiotherapy combined with immunotherapy: the dawn of cancer treatment. Signal Transduct Target Ther. 2022;7(1):258. https://doi.org/10.1038/s41392-022-01102-y.CrossRefPubMedPubMedCentral

Seyedin SN, Schoenhals JE, Lee DA, et al. Strategies for combining immunotherapy with radiation for anticancer therapy. Immunotherapy. 2015;7(9):967–80. https://doi.org/10.2217/imt.15.65.CrossRefPubMed

Li J, Liu X, Duan Y, et al. Abnormal expression of circulating and tumor-infiltrating carcinoembryonic antigen-related cell adhesion molecule 1 in patients with glioma. Oncol Lett. 2018;15(3):3496–503. https://doi.org/10.3892/ol.2018.7786.CrossRefPubMedPubMedCentral

John Cho BC, de Perrot M, et al. Radiotherapy in the era of immunotherapy: teaching an old dog new tricks. Eur Respir J. 2020. https://doi.org/10.1183/13993003.00320-2020.CrossRef

Wang L, Jiang J, Chen Y, et al. The roles of CC chemokines in response to radiation. Radiat Oncol. 2022;17(1):63. https://doi.org/10.1186/s13014-022-02038-x.CrossRefPubMedPubMedCentral

Herter-Sprie GS, Koyama S, Korideck H, et al. Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer. JCI Insight. 2016;1(9):e87415. https://doi.org/10.1172/jci.insight.87415.CrossRefPubMedPubMedCentral

10.

Mirzaei R, Susobhan Sarkar V, Yong W, et al. T cell exhaustion in glioblastoma: intricacies of immune checkpoints. Trends Immunol. 2017;38(2):104–15. https://doi.org/10.1016/j.it.2016.11.005.CrossRefPubMed

11.

Ortenberg R, Sapir Y, Raz L, et al. Novel immunotherapy for malignant melanoma with a monoclonal antibody that blocks CEACAM1 homophilic interactions. Mol Cancer Ther. 2012;11(6):1300–10. https://doi.org/10.1158/1535-7163.MCT-11-0526.CrossRefPubMed

12.

Huang YH, Zhu C, Kondo Y, et al. CEACAM1 regulates TIM-3-mediated tolerance and exhaustion. Nature. 2015;517(7534):386–90. https://doi.org/10.1038/nature13848.CrossRefPubMed

13.

Stylli SS, Luwor RB, Ware TM, et al. Mouse models of glioma. J Clin Neurosci. 2015;22(4):619–26. https://doi.org/10.1016/j.jocn.2014.10.013.CrossRefPubMed

14.

Markel G, Seidman R, Stern N, et al. Inhibition of human tumor-infiltrating lymphocyte effector functions by the homophilic carcinoembryonic cell adhesion molecule 1 interactions. J Immunol. 2006;177(9):6062–71. https://doi.org/10.4049/jimmunol.177.9.6062.CrossRefPubMed

15.

Andaloussi ElA, Lesniak MS. An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme. Neuro Oncol. 2006;8(3):234–43. https://doi.org/10.1215/15228517-2006-006.CrossRefPubMedPubMedCentral

16.

Sato E, Olson SH, Ahn J, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA. 2005;102(51):18538–43. https://doi.org/10.1073/pnas.0509182102.CrossRefPubMedPubMedCentral

17.

Fujita M, Scheurer ME, Decker SA, et al. Role of type 1 IFNs in antiglioma immunosurveillance–using mouse studies to guide examination of novel prognostic markers in humans. Clin Cancer Res. 2010;16(13):3409–19. https://doi.org/10.1158/1078-0432.CCR-10-0644.CrossRefPubMedPubMedCentral

18.

Gerber SA, Sedlacek AL, Cron KR, et al. IFN-γ mediates the antitumor effects of radiation therapy in a murine colon tumor. Am J Pathol. 2013;182(6):2345–54. https://doi.org/10.1016/j.ajpath.2013.02.041.CrossRefPubMedPubMedCentral

19.

Zisakis A, Piperi C, Themistocleous MS, et al. Comparative analysis of peripheral and localised cytokine secretion in glioblastoma patients. Cytokine. 2007;39(2):99–105. https://doi.org/10.1016/j.cyto.2007.05.012.CrossRefPubMed

20.

Li J, Liu M, Sun P, et al. Three-dimensional conformal radiotherapy combined with gemcitabine and docetaxel in the treatment of advanced bladder cancer and its effects on inflammatory factors and immune function. J Oncol. 2022;2022:9347218. https://doi.org/10.1155/2022/9347218.CrossRefPubMedPubMedCentral

21.

Zhao Z, Zhang K-N, Wang Q, et al. Chinese glioma genome atlas (CGGA): a comprehensive resource with functional genomic data from chinese glioma patients. Genom Proteom Bioinform. 2021;19(1):1–12. https://doi.org/10.1016/j.gpb.2020.10.005.CrossRef

Title: Radiotherapy combined with anti-CEACAM1 immunotherapy to induce survival advantage in glioma
Authors: Jinhu Li
Yi Chen
Yimin Fan
Hongqin Wang
Wei Mu
Xiaodong Liu
Publication date: 01-12-2023
Publisher: Springer US
Keywords: Glioma
Glioma
Glioma
Radiotherapy
Published in: Discover Oncology / Issue 1/2023
Print ISSN: 1868-8497
Electronic ISSN: 2730-6011
DOI: https://doi.org/10.1007/s12672-023-00638-x

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2023

Non-coding RNAs in breast cancer: with a focus on glucose metabolism reprogramming

Identification of galactosamine-(N-acetyl)-6-sulfatase (GALNS) as a novel therapeutic target in progression of nasopharyngeal carcinoma

ARAP1 negatively regulates stress fibers formation and metastasis in lung adenocarcinoma via controlling Rho signaling

BLCA prognostic model creation and validation based on immune gene-metabolic gene combination

miR-17 ~ 92 suppresses proliferation and invasion of cervical cancer cells by inhibiting cell cycle regulator Cdt2

OSR1 downregulation indicates an unfavorable prognosis and activates the NF-κB pathway in ovarian cancer

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials